[Antithrombotic drugs in urological surgery. Treatment interfering with haemostasis in urology?].
In storing or withholding a treatment that interferes haemostasis should be considered after assessing the benefit-risk ratio which requires the understanding of the efficacy, safety and pharmacology of heamostatic agents. This benefit to risk assessment is the key stone for the prevention of venous thrombosis, and peri-operative management of antiptatelet agents and vitamin K antagonists.
Zufferey
Paul
P
Département Anesthésie et Réanimation Chirurgicale, Groupe de Recherche de la Thrombose EA3065, Hôpital Bellevue, Boulevard Pasteur, CHU-St-Etienne 42055 02, France. paul.zufferey@chu-st-etienne.fr
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D013520:Urologic Surgical Procedures / Q000009:adverse effects*
D005343:Fibrinolytic Agents